HIGHLIGHTS
- who: . and collaborators from the Research, United States Medical University of Lublin, Poland have published the research: Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota, in the Journal: (JOURNAL)
- what: The authors administered febuxostat orally to HN rats, and evaluated its pharmacokinetics. The authors successfully demonstrated the protective effects of oral AST against hyperuricemia-induced nephropathy. This work has provided data for the rational application of febuxostat and partly explains the pathogenesis of HN based on the gut microbiota.
- how: The experiment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.